Table 3.
Body composition changes and major postoperative complications.
| Major Complications (n = 15) | No major Complications (n = 101) | p-value | |
|---|---|---|---|
| SMA, cm2 (median, IQR) | |||
| Pre-NT | 126 (54) | 134 (58)134 (58) | 0.8 |
| Post-NT | 125 (43) | 136 (50) | 0.7 |
| Δ | 15 (24) | 1 (12) | 0.066 |
| SMI, cm2/m2 (median, IQR) | |||
| Pre- NT | 44 (10) | 53 (35) | 0.035 |
| Post- NT | 49 (16) | 50 (12) | 0.7 |
| Δ | 0 (17) | 6 (5) | 0.002 |
| SAT, cm2 (median, IQR) | |||
| Pre- NT | 140 (112) | 168 (107) | 0.7 |
| Post- NT | 183 (89) | 164 (99) | 0.5 |
| Δ | 12 (48) | −11 (51) | 0.043 |
| VAT, cm2 (median, IQR) | |||
| Pre- NT | 81 (119) | 121 (122) | 0.5 |
| Post- NT | 96 (90) | 107 (109) | 0.9 |
| Δ | −1 (43) | −10 (39) | 0.2 |
| Low muscle mass (32) | |||
| Pre-neoadjuvant therapy | 40% | 28% | 0.432 |
| Post-neoadjuvant therapy | 33% | 34% | 0.961 |
NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; PNI, prognostic nutritional index. SMA, skeletal muscle area; SMI, skeletal muscle index; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue. Bold values indicate statistical significance.